Cutaneous T Cell Lymphoma Clinical Trials

12 recruiting

Cutaneous T Cell Lymphoma Trials at a Glance

14 actively recruiting trials for cutaneous t cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Tampa, New York, and Chicago. Lead sponsors running cutaneous t cell lymphoma studies include Dana-Farber Cancer Institute, Fondazione Italiana Linfomi - ETS, and Columbia University.

Browse cutaneous t cell lymphoma trials by phase

Treatments under study

About Cutaneous T Cell Lymphoma Clinical Trials

Looking for clinical trials for Cutaneous T Cell Lymphoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cutaneous T Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cutaneous T Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Cutaneous T Cell Lymphoma
Northwestern University300 enrolled1 locationNCT03932279
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
University of Alabama at Birmingham10 enrolled1 locationNCT05414500
Recruiting
Phase 1

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute38 enrolled1 locationNCT07047885
Recruiting
Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Mycosis FungoidesCutaneous T Cell LymphomaCTCL+1 more
Soligenix80 enrolled17 locationsNCT06470451
Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 2

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS400 enrolled18 locationsNCT06588868
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting
Not Applicable

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Chronic Lymphocytic LeukemiaLymphomaFollicular Lymphoma+6 more
UNC Lineberger Comprehensive Cancer Center40 enrolled1 locationNCT06860880
Recruiting
Not Applicable

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Peripheral T Cell LymphomaCutaneous T Cell Lymphoma
Dana-Farber Cancer Institute20 enrolled1 locationNCT04045470
Recruiting

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Leukemia/LymphomaCutaneous T Cell LymphomaATLL
Kyowa Kirin, Inc.150 enrolled1 locationNCT04014374
Recruiting

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis Fungoides
Peking University First Hospital100 enrolled3 locationsNCT06436677